Abstract:Heat shock protein (HSP)90 functions as a general oncogene by targeting several well-known oncoproteins for ubiquination and proteasomal degradation. However, the clinical significance of HSP90, as well as the mechanisms responsible for the tumor-promoting effects of HSP90 in hepatocellular carcinoma (HCC) remain unclear. In this study, HSP90 and hypoxia-inducible factor (HIF)-1 alpha expression in 60 samples of HCC tissues and matched normal tumor-adjacent tissue were assessed using immunohistochemistry (IHC) or western blot analysis. Flow cytometry, BrdU cell proliferation assay, caspase-3/7 activity assay and MTT assay were used to detect the apoptosis and proliferation of the HCC cells. The regulatory effect of HSP90 on HIF-1 alpha in the HCC cells was confirmed by immunofluorescence staining, western blot analysis and RT-qPCR. The interaction between HIF-1 alpha and HSP90 was analyzed by co-immunoprecipitation. A subcutaneous tumor xenograft model in nude mice was established and TUNEL assay was performed to evaluate cancer cell apoptosis and growth in vivo. We found that HSP90 expression was higher in the HCC tissues than in the normal tissues and that a high HSP90 expression correlated with poor clinicopathological characteristics, including venous infiltration, an advanced TNM stage and high pathological grading. Furthermore, we confirmed that patients with a negative expression of HSP90 had an improved 3-year survival, and that HSP90 was an independent factor for predicting the prognosis of patients with HCC. We demonstrated that HSP90 promoted HCC by inhibiting apoptosis and promoting cancer cell growth. Pearson's correlation coefficient analysis indicated that HSP90 expression positively correlated with HIF-1 alpha protein expression in the HCC tissues. Furthermore, we found that HSP90 regulated HIF-1 alpha protein abundance by inhibiting the ubiquitination and proteasomal degradation of HIF-1 alpha in HCC cells. Additionally, the upregulation of HIF-1 alpha expression partially abrogated HSP90 siRNA-induced HCC cell growth arrest and apoptosis in vitro and in vivo. These results indicate that HSP90 may be used as a prognostic marker and that HIF-1 alpha may be one of the potential therapeutic targets of HSP90 in HCC.

The Influences of HSP90 and Its Inhibitors on Tumor Immune Reactions

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

Study on the Hsp90 Inhibitors

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

Progress of study on Hsp90 inhibitors

Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target

Discovery and development of natural heat shock protein 90 inhibitors in cancer treatment

Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress

Hsp90 regulates autophagy and plays a role in cancer therapy

HSP90 multi-functionality in cancer

New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential

An update on the status of HSP90 inhibitors in cancer clinical trials

Inhibition of Heat Shock Protein 90 As a Novel Platform for the Treatment of Cancer.

HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy

HSP90 and the chaperoning of cancer

Hsp90 Inhibits Apoptosis And Promotes Growth By Regulating Hif-1 Alpha Abundance In Hepatocellular Carcinoma

Natural HSP90 inhibitors as a potential therapeutic intervention in treating cancers: A comprehensive review

Roles of heat shock proteins in tumor immune microenvironment